Positive results from trial of cabozantinib plus nivolumab combination in untreated metastatic kidney cancer
Results from the pivotal phase 3 CheckMate-9ER clinical trial evaluating [...]
Atezolizumab and bevacizumab for non-clear cell renal cell carcinoma
In this video interview from Practice Update, Dr Brad McGregor [...]
ASCO GU 2020: VEGF tyrosine kinase inhibitors as second-line treatment after immunotherapy for advanced kidney cancer
A retrospective analysis of data from the International Metastatic Renal [...]
Comparison of first-line immunotherapy combinations for advanced kidney cancer
In this paper, three clinical trials with immunotherapy combinations for [...]
The effect of antibiotic use on outcomes with kidney cancer drug treatments
A recent study has looked at the use of antibiotics [...]
ESMO 2019: First-line avelumab plus axitinib in sarcomatoid kidney cancer – results from JAVELIN Renal 101
Results from the JAVELIN Renal 101 study to evaluate avelumab [...]
ASCO 2019: Safety and efficacy of immune checkpoint inhibitors in patients with pre-existing autoimmune disorders
This study was presented at the American Society of Clinical [...]
Telaglenastat/cabozantinib combination shows early activity in metastatic kidney cancer
Telaglenastat is an oral glutaminase inhibitor and this is the [...]
